Hybrid galactoside inhibitor of galectins

Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin,...

Full description

Saved in:
Bibliographic Details
Main Authors Nilsson, Ulf, Zetterberg, Fredrik, Leffler, Hakon
Format Patent
LanguageEnglish
Published 13.10.2020
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online AccessGet full text

Cover

More Information
Summary:Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Bibliography:Application Number: US201816200464